- Home
- IOVA
as 02-20-2025 4:00pm EST
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.
Upcoming Earnings Alert:
Get ready for potential market movements as Iovance Biotherapeutics Inc. IOVA prepares to release earnings report on 26 Feb 2025.
| Founded: | 2007 | Country: | United States |
| Employees: | N/A | City: | SAN CARLOS |
| Market Cap: | 2.6B | IPO Year: | N/A |
| Target Price: | $23.06 | AVG Volume (30 days): | 7.2M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.48 | EPS Growth: | N/A |
| 52 Week Low/High: | $5.05 - $18.33 | Next Earning Date: | 02-26-2025 |
| Revenue: | $90,858,000 | Revenue Growth: | 12751.20% |
| Revenue Growth (this year): | 13803.28% | Revenue Growth (next year): | 167.55% |
Latest Iovance Biotherapeutics Inc. News
IOVA Breaking Stock News: Dive into IOVA Ticker-Specific Updates for Smart Investing
GlobeNewswire
2 days ago
Iovance Biotherapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates on February 27, 2025
Simply Wall St.
3 days ago
High Growth Tech Stocks In The United States To Watch
GlobeNewswire
8 days ago
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
GlobeNewswire
10 days ago
Iovance Biotherapeutics Appoints Dan Kirby as Chief Commercial Officer
Motley Fool
21 days ago
What's Wrong With Iovance Biotherapeutics Stock?
Motley Fool
22 days ago
Where Will Iovance Biotherapeutics Be in 5 Years?
Motley Fool
25 days ago
Meet the Growth Stock That Could Soar 280%, According to Wall Street Analysts
Simply Wall St.
a month ago
Insider Stock Buying Reaches US$48.3m On Iovance Biotherapeutics
Compare IOVA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "IOVA Iovance Biotherapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.